Asked by: Steve Yemm (Labour - Mansfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he expects treatments for fatty liver disease to be approved for use on the NHS; what assessment he has made of the readiness of the NHS to make such treatments available; and what steps he is taking to ensure eligible patients will receive these treatments once approved.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Newly licensed medicines are appraised by the National Institute for Health and Care Excellence (NICE), which is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE aims wherever possible to issue draft guidance on new medicines close to the time of licensing. The NHS in England is legally required to fund drugs recommended by NICE, usually within three months of final guidance.
NICE is currently evaluating potential new treatments for metabolic dysfunction-associated steatohepatitis (MASH) in anticipation of the medicines being granted a marketing authorisation by the Medicines and Healthcare Products Regulatory Agency (MHRA) with guidance expected later this year. NHS England is actively preparing to support the potential introduction of new treatments for MASH, including fatty liver disease with fibrosis, alongside the ongoing NICE appraisal process.
The Department and NHS England will continue to work to ensure that, once approved, effective new treatments for fatty liver disease are introduced in a way that is fair, affordable and protects the wider NHS, while ensuring that patients with the greatest clinical need are able to benefit as quickly as possible.
Asked by: Baroness Shawcross-Wolfson (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 13 January (HL13304), what plans there are for co-operation between the Independent Review for Mental Health Conditions, ADHD and Autism and the Young People and Work Report led by Alan Milburn.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Independent Review for Mental Health Conditions, ADHD, and Autism, and the Young People and Work Report led by Alan Milburn are complementary. The chairs and the secretariats are in regular discussion to ensure cooperation.
Asked by: Will Forster (Liberal Democrat - Woking)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding was allocated to each Integrated Care Board in England for long covid services in the 2024-25 financial year.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Integrated care boards (ICBs) are allocated funding by the National Health Service based on a statistical formula which takes into account population size and needs, so that funding distribution is fair and objective. Further details on ICB funding allocation can be found at the following link:
https://www.england.nhs.uk/allocations/
The allocation of funding for specialised services, including long COVID, are at the discretion of local ICBs to best meet the needs of their local population.
Commissioning guidance, from December 2023, presents guidelines for the commissioning and oversight of post-COVID services by ICBs in England for adults, and children and young people from April 2024. Since then, in line with the NHS operating framework and the establishment of integrated care systems, the commissioning of post-COVID services has been the responsibility of ICBs. However, according to this guidance, post-COVID services should comprise an integrated pathway of assessment, medical treatment, and multifaceted rehabilitation, including psychology, with direct access to required diagnostics. Referral should be via a single point of access which is managed by clinician-led triage.
Asked by: Will Forster (Liberal Democrat - Woking)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether future NHS planning guidance will require Integrated Care Boards to provide dedicated long covid pathways.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Integrated care boards (ICBs) are allocated funding by the National Health Service based on a statistical formula which takes into account population size and needs, so that funding distribution is fair and objective. Further details on ICB funding allocation can be found at the following link:
https://www.england.nhs.uk/allocations/
The allocation of funding for specialised services, including long COVID, are at the discretion of local ICBs to best meet the needs of their local population.
Commissioning guidance, from December 2023, presents guidelines for the commissioning and oversight of post-COVID services by ICBs in England for adults, and children and young people from April 2024. Since then, in line with the NHS operating framework and the establishment of integrated care systems, the commissioning of post-COVID services has been the responsibility of ICBs. However, according to this guidance, post-COVID services should comprise an integrated pathway of assessment, medical treatment, and multifaceted rehabilitation, including psychology, with direct access to required diagnostics. Referral should be via a single point of access which is managed by clinician-led triage.
Asked by: Laurence Turner (Labour - Birmingham Northfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 15 January to Question 101203, on Latex: Allergies, if he will place a copy of the Expert Advisory Group on Allergy's December 2025 minutes in the House of Commons Library.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Terms of Reference for the Expert Advisory Group on Allergy, which is overseen and supported by external stakeholders, states that the meetings are confidential. Therefore, the meeting minutes are not shared publicly.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure General Practitioners are sufficiently trained on Functional Neurological Disorder.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department recognises the need to improve awareness and understanding of functional neurological disorder (FND) across the health system.
The Royal College of General Practitioners provides a learning course that includes a dedicated module on recognising and explaining FND, helping general practitioners (GPs) to improve early identification and understanding of the condition. Further support is provided through guidance published by the National Institute for Care Excellence (NICE) on suspected neurological conditions: recognition and referral, reference code NG127, which includes detailed recommendations on recognising symptoms commonly present in FND and appropriate referral pathways.
NICE also provides a Clinical Knowledge Summary (CKS) on FND, offering practical, evidence‑based advice on diagnosis and management, supporting clinicians in distinguishing FND from structural or degenerative neurological disease.
FND is also included in a NICE guideline on rehabilitation for chronic neurological disorders and acquired brain injury, reference code NG252, published in October 2025. This further strengthens the evidence base and ensure clinicians have clear, up‑to‑date guidance on assessment and management within a broader neurological context.
Together, these resources ensure that health professionals, across primary, secondary, and specialist services, have access to robust, evidence‑based tools to support accurate differentiation between FND and other neurological conditions.
GPs are required to undertake continuing professional development to maintain and update their clinical knowledge, and they can access a range of training resources through professional bodies, royal colleges, and National Health Service‑funded education platforms. Decisions about mandatory training requirements are made only where there is a clear and evidence‑based need, and the current approach remains to ensure that GPs have the flexibility to tailor their learning to the needs of their patient populations.
Asked by: Edward Morello (Liberal Democrat - West Dorset)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to address regional variation in access to continuous glucose monitoring, including in Dorset.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Integrated care boards are responsible for commissioning health services to meet the needs of their populations. In doing so they must have regard to the National Institute for Health and Care Excellence (NICE) guidance, including for diabetes. The National Diabetes Audit (NDA), and the National Paediatric Diabetes Audit (NPDA) along with NHS Digital’s NDA and NPDA dashboards provide comprehensive data on care processes and outcomes and highlight variation. The dashboards help commissioners, providers, and paediatric diabetes units benchmark themselves and target improvements.
NHS Dorset has a policy in place for the provision of prescribable continuous glucose monitoring (CGM) for both type 1 and type 2 diabetes.
In order to ensure that Dorset patients are being treated appropriately, use of CGM is tracked against patient eligibility criteria as set out in NICE guidance and the NHS Dorset CGM policy.
Asked by: Mike Martin (Liberal Democrat - Tunbridge Wells)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to extend NHS eligibility for the Shingrix shingles vaccine to older adults who previously received Zostavax.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Joint Committee on Vaccination and Immunisation (JCVI) is an independent departmental expert committee which advises the Government on matters related to vaccination and immunisation.
In November 2024, the JCVI provided advice to the Government on eligibility for the shingles vaccination programme. This included advice that the Government should consider expanding the shingles vaccination offer to include older adult cohorts aged 80 years old and over, regardless of whether these older individuals have previously been eligible for, or have been vaccinated with, Zostavax. The Department is carefully considering this advice as it sets the policy on who should be offered shingles vaccinations.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure health professionals are adequately trained on the differences between Functional Neurological Disorder and other neurological conditions.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department recognises the need to improve awareness and understanding of functional neurological disorder (FND) across the health system.
The Royal College of General Practitioners provides a learning course that includes a dedicated module on recognising and explaining FND, helping general practitioners (GPs) to improve early identification and understanding of the condition. Further support is provided through guidance published by the National Institute for Care Excellence (NICE) on suspected neurological conditions: recognition and referral, reference code NG127, which includes detailed recommendations on recognising symptoms commonly present in FND and appropriate referral pathways.
NICE also provides a Clinical Knowledge Summary (CKS) on FND, offering practical, evidence‑based advice on diagnosis and management, supporting clinicians in distinguishing FND from structural or degenerative neurological disease.
FND is also included in a NICE guideline on rehabilitation for chronic neurological disorders and acquired brain injury, reference code NG252, published in October 2025. This further strengthens the evidence base and ensure clinicians have clear, up‑to‑date guidance on assessment and management within a broader neurological context.
Together, these resources ensure that health professionals, across primary, secondary, and specialist services, have access to robust, evidence‑based tools to support accurate differentiation between FND and other neurological conditions.
GPs are required to undertake continuing professional development to maintain and update their clinical knowledge, and they can access a range of training resources through professional bodies, royal colleges, and National Health Service‑funded education platforms. Decisions about mandatory training requirements are made only where there is a clear and evidence‑based need, and the current approach remains to ensure that GPs have the flexibility to tailor their learning to the needs of their patient populations.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make training on Functional Neurological Disorder mandatory for General Practitioners.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department recognises the need to improve awareness and understanding of functional neurological disorder (FND) across the health system.
The Royal College of General Practitioners provides a learning course that includes a dedicated module on recognising and explaining FND, helping general practitioners (GPs) to improve early identification and understanding of the condition. Further support is provided through guidance published by the National Institute for Care Excellence (NICE) on suspected neurological conditions: recognition and referral, reference code NG127, which includes detailed recommendations on recognising symptoms commonly present in FND and appropriate referral pathways.
NICE also provides a Clinical Knowledge Summary (CKS) on FND, offering practical, evidence‑based advice on diagnosis and management, supporting clinicians in distinguishing FND from structural or degenerative neurological disease.
FND is also included in a NICE guideline on rehabilitation for chronic neurological disorders and acquired brain injury, reference code NG252, published in October 2025. This further strengthens the evidence base and ensure clinicians have clear, up‑to‑date guidance on assessment and management within a broader neurological context.
Together, these resources ensure that health professionals, across primary, secondary, and specialist services, have access to robust, evidence‑based tools to support accurate differentiation between FND and other neurological conditions.
GPs are required to undertake continuing professional development to maintain and update their clinical knowledge, and they can access a range of training resources through professional bodies, royal colleges, and National Health Service‑funded education platforms. Decisions about mandatory training requirements are made only where there is a clear and evidence‑based need, and the current approach remains to ensure that GPs have the flexibility to tailor their learning to the needs of their patient populations.